In a Quandary of Drug Quality, Price Control, Innovation and Patient Interest in India

The patients in India have every reason to apprehend, whether the prescription drugs that they consume are efficacious, safe and conform to the government approved prices, alongside another important question: Do they affordable access to the fruits of innovation? The … Continue reading

How Cost-Effective Are New Cancer Drugs?

The main reason why cancer is so serious a disease, is the ability of the malignant cells to spread in the body, both locally by moving into nearby normal tissue, and regionally to nearby lymph nodes, tissues, or organs, affecting even … Continue reading

Pharma Sales Communication: Would ‘Cafeteria Approach’ Be More Productive Today?

For sales communication, quality of access of pharma Medical Representatives (MRs) to many important and busy doctors has been steadily declining over the past several years, all over the world, and India is no exception. This is mainly because the number of … Continue reading

Are We Taking Safe and Effective Medicines?

The above headline is in no way intended to mean that this discussion is on spurious or counterfeit drugs. Today’s deliberation is on the licensed drugs, which are manufactured in India, for the patients of the country, by the manufacturers … Continue reading

In VUCA World: Changing Dynamics of Prescription Generation Process

The acronym VUCA is often being used to emphasize upon the Volatility, Uncertainty, Complexity and Ambiguity in various situations. The term has been derived from military vocabulary and is being used since 1990s in the business management parlance. VUCA is also … Continue reading

Are Preventive Medicines always cost effective to be an area of focus in healthcare management?

American Board of Preventive Medicine defines ‘Preventive Medicine’ as follows: “Preventive Medicine is the specialty of medical practice that focuses on the health of individuals, communities, and defined populations. Its goal is to protect, promote, and maintain health and well-being … Continue reading

The Game Changer: Effective transition from ‘blockbuster’ to an integrated ‘niche buster’ plus ‘generic drugs’ business model

Since quite some time global pharmaceutical majors have been operating within the confines of high risk – high reward R&D based business model with blockbuster drugs (annual sales of over US$ 1 billion). Blockbuster brands, mostly in the chronic-care segments … Continue reading